STAT+: Vertex kidney disease drug scrutinized for infection risk
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
<p>Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.</p>